Answers are grounded in this paper and cite their sources.
Average cancer risks for BRCA1/BRCA2 and Lynch Syndrome pathogenic-variant carriers are above established thresholds of clinical intervention for patient benefit, even in those without a cancer family-history. A recent analysis based on UK-Biobank data suggesting that risk in carriers is primarily conferred by cancer family-history has multiple interpretation and methodological flaws.
No takes yet. Share an insight, caveat, or question.
Manchanda et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: